Tech Company Financing Transactions
Epic Sciences Funding Round
Epic Sciences closed a $30 million Series C investment round on 7/30/2014. Investors included Arcus Ventures, Domain Associates and Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
7/30/2014
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Domain Associates (Kim Kamdar)
RusnanoMedInvest (Evgeny Zaytsev)
Proceeds Purpose
With the proceeds of the financing, Epic will commercialize its circulating rare cell analysis platform with special focus on developing products and services to detect circulating tumor cells (CTC) in cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9381 Judicial Dr. 200
La Jolla, CA 92121
USA
La Jolla, CA 92121
USA
Phone
Website
Email Address
Overview
Developing new diagnostic blood tests that can identify and characterize circulating tumor cells to improve cancer detection and to personalize medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lloyd Sanders
Chief Financial Officer
Joel Smith
Chief Medical Officer
Richard Wenstrup
Chief Technical Officer
Chockalingam Palaniappan
Browse more venture capital transactions:
Prev: 7/30/2014: Zipit Wireless venture capital transaction
Next: 7/30/2014: ZipZap venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs